PCSK9 and familial hyperaldosteronism: 198 FH patients with LDLR variants vs. 42 with PCSK9 variants vs. 4015 controls: 12.6 (9.4–33.9) vs. 21.1 (11.7–34.9) vs. 5 (2.7–8.1) mg/dL, p = 0.002 for the comparison between FH-LDLR or FH-PCSK9 with control group.